Health care stocks were mixed pre-bell Friday, with the Health Care Select Sector SPDR Fund (XLV) slightly higher and the iShares Biotechnology ETF (IBB) declining by 1.5%.
Geron (GERN) shares were up past 19% after the company said it received approval from the US Food and Drug Administration for its drug Rytelo to treat adult patients with lower-risk myelodysplastic syndrome, a type of leukemia.
Biomea Fusion (BMEA) stock was down more than 65% after the company said it was notified that the US Food and Drug Administration placed a full clinical hold on the phase I/II trials of its investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes.
Semler Scientific (SMLR) shares were down more than 2% after the company said it filed a registration statement for the offering of up to $150 million worth of various securities, including common shares, debt securities, units, and warrants.
Comments